{"id":"https://openalex.org/W4405374547","doi":"https://doi.org/10.1016/j.iotech.2024.100834","title":"91P Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022","display_name":"91P Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022","publication_year":2024,"publication_date":"2024-12-01","ids":{"openalex":"https://openalex.org/W4405374547","doi":"https://doi.org/10.1016/j.iotech.2024.100834"},"language":"en","primary_location":{"id":"doi:10.1016/j.iotech.2024.100834","doi":"https://doi.org/10.1016/j.iotech.2024.100834","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2024.100834","pdf_url":"https://www.esmoiotech.org/article/S2590-0188(24)00131-X/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4405374547"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.esmoiotech.org/article/S2590-0188(24)00131-X/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014038206","display_name":"Anne\u2010Claire Toffart","orcid":"https://orcid.org/0000-0003-4377-0227","observed_orcids":["https://orcid.org/0000-0003-4377-0227"]},"institutions":[{"id":"https://openalex.org/I2800555055","display_name":"Centre Hospitalier Universitaire de Grenoble","ror":"https://ror.org/041rhpw39","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2800555055"]},{"id":"https://openalex.org/I4210162920","display_name":"H\u00f4pital Albert Michallon","ror":"https://ror.org/05kfvx519","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2800555055","https://openalex.org/I4210162920"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"A.C. Toffart","raw_affiliation_strings":["Pulmonology Unit, CHU Grenoble-Alpes - Le Site Nord \u00e0 La Tronche - Hopital Michallon, La Tronche, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pulmonology Unit, CHU Grenoble-Alpes - Le Site Nord \u00e0 La Tronche - Hopital Michallon, La Tronche, France","institution_ids":["https://openalex.org/I2800555055","https://openalex.org/I4210162920"]}]},{"author_position":"middle","author":{"id":null,"display_name":"G. Casanova","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"G. Casanova","raw_affiliation_strings":["Sant\u00e9 Publique, APHP, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sant\u00e9 Publique, APHP, Paris, France","institution_ids":["https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075846590","display_name":"M. Pierre","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098725","display_name":"Bristol-Myers Squibb (France)","ror":"https://ror.org/013b57229","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210098725"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"M. Pierre","raw_affiliation_strings":["Public Health, Bristol Myers Squibb, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Public Health, Bristol Myers Squibb, Paris, France","institution_ids":["https://openalex.org/I4210098725"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041757016","display_name":"H. Lemasson","orcid":"https://orcid.org/0000-0002-9656-2432","observed_orcids":["https://orcid.org/0000-0002-9656-2432"]},"institutions":[{"id":"https://openalex.org/I4210098725","display_name":"Bristol-Myers Squibb (France)","ror":"https://ror.org/013b57229","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210098725"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"H. Lemasson","raw_affiliation_strings":["Pulic Health, Bristol Myers Squibb SARL, Rueil-Malmaison, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pulic Health, Bristol Myers Squibb SARL, Rueil-Malmaison, France","institution_ids":["https://openalex.org/I4210098725"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019775949","display_name":"V\u00e9ronique Moreau-Mallet","orcid":"https://orcid.org/0009-0002-2972-1664","observed_orcids":["https://orcid.org/0009-0002-2972-1664"]},"institutions":[{"id":"https://openalex.org/I4210098725","display_name":"Bristol-Myers Squibb (France)","ror":"https://ror.org/013b57229","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210098725"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"V. Moreau-Mallet","raw_affiliation_strings":["M\u00e9dical, Bristol Myers Squibb SARL, Rueil-Malmaison, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M\u00e9dical, Bristol Myers Squibb SARL, Rueil-Malmaison, France","institution_ids":["https://openalex.org/I4210098725"]}]},{"author_position":"middle","author":{"id":null,"display_name":"N. Pag\u00e8s","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Pag\u00e8s","raw_affiliation_strings":["Pharmaco-\u00c9pid\u00e9miologie, HEVA, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaco-\u00c9pid\u00e9miologie, HEVA, Lyon, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021865027","display_name":"Ronan Jolivel","orcid":"https://orcid.org/0000-0001-6389-5372","observed_orcids":["https://orcid.org/0000-0001-6389-5372"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Jolivel","raw_affiliation_strings":["Pharmaco-\u00c9pid\u00e9miologie, HEVA, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaco-\u00c9pid\u00e9miologie, HEVA, Lyon, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000216802","display_name":"A. Pan\u00e8s","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Pan\u00e8s","raw_affiliation_strings":["Pharmaco-\u00c9pid\u00e9miologie, HEVA, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaco-\u00c9pid\u00e9miologie, HEVA, Lyon, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060502422","display_name":"M. Chartier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098725","display_name":"Bristol-Myers Squibb (France)","ror":"https://ror.org/013b57229","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4210098725"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"M. Chartier","raw_affiliation_strings":["HEOR, Bristol Myers Squibb SARL, Rueil-Malmaison, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HEOR, Bristol Myers Squibb SARL, Rueil-Malmaison, France","institution_ids":["https://openalex.org/I4210098725"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043045128","display_name":"Maurice P\u00e9rol","orcid":"https://orcid.org/0000-0002-3296-423X","observed_orcids":["https://orcid.org/0000-0002-3296-423X"]},"institutions":[{"id":"https://openalex.org/I4210105738","display_name":"Centre L\u00e9on B\u00e9rard","ror":"https://ror.org/01cmnjq37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210105738"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"M. P\u00e9rol","raw_affiliation_strings":["Medical Oncology Dept., Centre L\u00e9on B\u00e9rard, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Dept., Centre L\u00e9on B\u00e9rard, Lyon, France","institution_ids":["https://openalex.org/I4210105738"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3170,"currency":"USD","value_usd":3170},"apc_paid":{"value":3170,"currency":"USD","value_usd":3170},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":null,"first_page":"100834","last_page":"100834"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.40059998631477356,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.40059998631477356,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10912","display_name":"Telemedicine and Telehealth Implementation","score":0.1256999969482422,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11296","display_name":"COVID-19 and healthcare impacts","score":0.0471000000834465,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hospital-at-home","display_name":"home hospitalization","score":0.7990000247955322},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/regional-disparities","display_name":"regional disparities","score":0.5920000076293945},{"id":"https://openalex.org/keywords/health-care-access","display_name":"health care access","score":0.5669999718666077},{"id":"https://openalex.org/keywords/cancer-care","display_name":"cancer care","score":0.48500001430511475}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48082292079925537},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.47029897570610046},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.38984164595603943},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3411939740180969},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1823345124721527},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.11818644404411316}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.iotech.2024.100834","doi":"https://doi.org/10.1016/j.iotech.2024.100834","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2024.100834","pdf_url":"https://www.esmoiotech.org/article/S2590-0188(24)00131-X/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.iotech.2024.100834","doi":"https://doi.org/10.1016/j.iotech.2024.100834","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2024.100834","pdf_url":"https://www.esmoiotech.org/article/S2590-0188(24)00131-X/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4405374547.pdf","grobid_xml":"https://content.openalex.org/works/W4405374547.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3212299956","https://openalex.org/W4205161519","https://openalex.org/W7212243822","https://openalex.org/W4223441829","https://openalex.org/W7117320109","https://openalex.org/W2954747398","https://openalex.org/W2948718278","https://openalex.org/W4280542166","https://openalex.org/W4254809593","https://openalex.org/W7034590384"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2024-12-14T00:00:00"}
